Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports

02-04-2024 | Interstitial Lung Disease and Pulmonary Fibrosis | REVIEW

Interstitial Lung Abnormalities (ILA) and Pulmonary Fibrosis

Authors: Noriaki Wada, Kyung Soo Lee, Hiroto Hatabu

Published in: Current Pulmonology Reports

Login to get access

Abstract

Purpose of Review

This review identifies the similarities and differences between interstitial lung abnormalities (ILA) and pulmonary fibrosis in terms of clinical relevance, radiological features, histological features, genetics, pathophysiology, and biomarkers, and presents clinical management with a focus on ILA and future perspectives.

Recent Findings

ILA and pulmonary fibrosis, especially idiopathic pulmonary fibrosis, may share common biological, radiological, and histopathological features and are increasingly understood as a spectrum of fibrotic interstitial lung diseases. ILA, especially subpleural fibrotic subtype, are associated with radiological progression and increased mortality and are clinically important for early risk detection of pulmonary fibrosis. Traction bronchiectasis/bronchiolectasis index (TBI) is particularly valuable to further stratify the prognosis of ILA individuals.

Summary

To improve the prognosis of patients with pulmonary fibrosis, further advances in a multifaceted approach to understand the spectrum of pulmonary fibrosis and stratify the risk of progression to pulmonary fibrosis in ILA individuals are warranted.
Literature
1.
Hatabu H, Hunninghake GM, Lynch DA. Interstitial lung abnormality: recognition and perspectives. Radiology. 2019;291(1):1–3.PubMedCrossRef
2.
•• Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med. 2020;8(7):726–37. This Position Paper by the Fleischner Society addressed important issues regarding ILA, including standardization of the definition and terminology, predisposing risk factors, clinical outcomes, management, and future research needs.PubMedPubMedCentralCrossRef
3.
•• Hata A, Schiebler ML, Lynch DA, Hatabu H. Interstitial lung abnormalities: state of the art. Radiology. 2021;301(1):19–34. This article reviewed the latest knowledge about ILA and explained the role of the radiologist in the management of ILA, including how ILA are described in radiologic reports.PubMedCrossRef
4.
5.
• Hino T, Lee KS, Han J, Hata A, Ishigami K, Hatabu H,. Spectrum of pulmonary fibrosis from interstitial lung abnormality to usual interstitial pneumonia: importance of identification and quantification of traction bronchiectasis in patient management. Korean J Radiol. 2021;22(5):811–28. This article described the spectrum of pulmonary fibrosis from ILA to UIP based on the radiological and pathological features of UIP, NSIP, and ILA, and special focus was given to traction bronchiectasis/bronchiolectasis on HRCT.PubMedCrossRef
6.
• Hino T, Lee KS, Yoo H, Han J, Franks TJ, Hatabu H. Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP). Eur J Radiol Open. 2021;8:100336. This article described the spectrum of pulmonary fibrosis from ILA to UIP based on the radiological and pathological features of UIP, NSIP, and ILA, and special focus was given to traction bronchiectasis/bronchiolectasis on HRCT.PubMedPubMedCentralCrossRef
7.
Tomassetti S, Poletti V, Ravaglia C, Sverzellati N, Piciucchi S, Cozzi D, et al. Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives. Eur Respir Rev. 2022;31(164): 210206.PubMedPubMedCentralCrossRef
8.
9.
• Hata A, Hino T, Yanagawa M, Nishino M, Hida T, Hunninghake GM, et al. Interstitial lung abnormalities at CT: subtypes, clinical significance, and associations with lung cancer. Radiographics. 2022;42(7):1925–39. This article addressed the association between ILA and lung cancer in detail as well as an overview of ILA.PubMedCrossRef
10.
Washko GR, Lynch DA, Matsuoka S, Ross JC, Umeoka S, Diaz A, et al. Identification of early interstitial lung disease in smokers from the COPDGene study. Acad Radiol. 2010;17(1):48–53.PubMedCrossRef
11.
Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011;364(10):897–906.PubMedPubMedCentralCrossRef
12.
Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013;368(23):2192–200.PubMedPubMedCentralCrossRef
13.
Jin GY, Lynch D, Chawla A, Garg K, Tammemagi MC, Sahin H, et al. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology. 2013;268(2):563–71.PubMedPubMedCentralCrossRef
14.
Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and progression of interstitial lung abnormalities in the Framingham Heart study. Am J Respir Crit Care Med. 2016;194(12):1514–22.PubMedPubMedCentralCrossRef
15.
Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA. 2016;315(7):672–81.PubMedPubMedCentralCrossRef
16.
Zhang Y, Wan H, Richeldi L, Zhu M, Huang Y, Xiong X, et al. Reticulation is a risk factor of progressive subpleural nonfibrotic interstitial lung abnormalities. Am J Respir Crit Care Med. 2022;206(2):178–85.PubMedCrossRef
17.
• Lee JE, Chae KJ, Suh YJ, Jeong WG, Lee T, Kim YH, et al. Prevalence and long-term outcomes of CT interstitial lung abnormalities in a health screening cohort. Radiology. 2023;306(2):e221172. This study showed that the prevalence of ILA in an Asian health screening cohort was approximately 3% and that fibrotic ILA was associated with imaging progression, lung cancer development, and mortality within 10-year follow-up.
18.
Putman RK, Gudmundsson G, Axelsson GT, Hida T, Honda O, Araki T, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med. 2019;200(2):175–83.PubMedPubMedCentralCrossRef
19.
Bowman WS, Echt GA, Oldham JM. Biomarkers in progressive fibrosing interstitial lung disease: optimizing diagnosis, prognosis, and treatment response. Front Med (Lausanne). 2021;8:680997.PubMedCrossRef
20.
Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18–47.PubMedPubMedCentralCrossRef
21.
Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.PubMedPubMedCentralCrossRef
22.
23.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27.PubMedCrossRef
24.
Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, Group IPFCW. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51(5):1800692.PubMedCrossRef
25.
Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.PubMedCrossRef
26.
27.
Sverzellati N, Guerci L, Randi G, Calabro E, La Vecchia C, Marchiano A, et al. Interstitial lung diseases in a lung cancer screening trial. Eur Respir J. 2011;38(2):392–400.PubMedCrossRef
28.
Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med. 2010;104(11):1712–21.PubMedCrossRef
29.
Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941–52.PubMedCrossRef
30.
Hoyer N, Wille MMW, Thomsen LH, Wilcke T, Dirksen A, Pedersen JH, et al. Interstitial lung abnormalities are associated with increased mortality in smokers. Respir Med. 2018;136:77–82.PubMedCrossRef
31.
Ash SY, Harmouche R, Putman RK, Ross JC, Diaz AA, Hunninghake GM, et al. Clinical and genetic associations of objectively identified interstitial changes in smokers. Chest. 2017;152(4):780–91.PubMedPubMedCentralCrossRef
32.
Putman RK, Hunninghake GM, Dieffenbach PB, Barragan-Bradford D, Serhan K, Adams U, et al. Interstitial lung abnormalities are associated with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2017;195(1):138–41.PubMedPubMedCentralCrossRef
33.
Marchioni A, Tonelli R, Ball L, Fantini R, Castaniere I, Cerri S, et al. Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome? Crit Care. 2018;22(1):80.PubMedPubMedCentralCrossRef
34.
Axelsson GT, Putman RK, Aspelund T, Gudmundsson EF, Hida T, Araki T, et al. The associations of interstitial lung abnormalities with cancer diagnoses and mortality. Eur Respir J. 2020;56(6):1902154.PubMedPubMedCentralCrossRef
35.
Whittaker Brown SA, Padilla M, Mhango G, Powell C, Salvatore M, Henschke C, et al. Interstitial lung abnormalities and lung cancer risk in the National Lung Screening Trial. Chest. 2019;156(6):1195–203.PubMedCrossRef
36.
Hoyer N, Thomsen LH, Wille MMW, Wilcke T, Dirksen A, Pedersen JH, et al. Increased respiratory morbidity in individuals with interstitial lung abnormalities. BMC Pulm Med. 2020;20(1):67.PubMedPubMedCentralCrossRef
37.
Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001;17(6):1216–9.PubMedCrossRef
38.
Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6(2):138–53.PubMedCrossRef
39.
Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36–69.PubMedPubMedCentralCrossRef
40.
Adegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Noth I, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019;16(5):580–8.PubMedPubMedCentralCrossRef
41.
• Hida T, Nishino M, Hino T, Lu J, Putman RK, Gudmundsson EF, et al. (2020) Traction Bronchiectasis/Bronchiolectasis is Associated with interstitial lung abnormality mortality. Eur J Radiol. 2020;129:109073. This is the first study to report that higher baseline TBI was associated with shorter overall survival in ILA subjects and that TBI may serve as a useful imaging marker for risk stratification in ILA.PubMedPubMedCentralCrossRef
42.
• Hino T, Hida T, Nishino M, Lu J, Putman RK, Gudmundsson EF, et al. Progression of traction bronchiectasis/bronchiolectasis in interstitial lung abnormalities is associated with increased all-cause mortality: Age Gene/Environment Susceptibility-Reykjavik study. Eur J Radiol Open. 2021;8:100334. This is the first study to report that traction bronchiectasis progression was associated with higher baseline TBI and shorter overall survival in ILA subjects.PubMedPubMedCentralCrossRef
43.
• Hata A, Hino T, Putman RK, Yanagawa M, Hida T, Menon AA, et al. Traction bronchiectasis/bronchiolectasis on CT scans in relationship to clinical outcomes and mortality: the COPDGene study. Radiology. 2022;304(3):694–701. This article reconfirmed that baseline traction bronchiectasis/bronchiolectasis was associated with poor clinical outcomes and shorter overall survival in ILA subjects. This study also showed good reproducibility of TBI.PubMedCrossRef
44.
• Hata A, Hino T, Li Y, Johkoh T, Christiani DC, Lynch DA, et al. Traction bronchiectasis/bronchiolectasis in interstitial lung abnormality: follow-up in the COPDGene. Am J Respir Crit Care Med. 2023;207(10):1395–8. This paper reported that TBI and the progression were associated with pulmonary physiological decrements at follow-up in ILA subjects.PubMedCrossRef
45.
Piciucchi S, Tomassetti S, Ravaglia C, Gurioli C, Gurioli C, Dubini A, et al. from “traction bronchiectasis” to honeycombing in idiopathic pulmonary fibrosis: a spectrum of bronchiolar remodeling also in radiology? BMC Pulm Med. 2016;16(1):87.PubMedPubMedCentralCrossRef
46.
Johkoh T, Sumikawa H, Fukuoka J, Tanaka T, Fujimoto K, Takahashi M, et al. Do you really know precise radiologic-pathologic correlation of usual interstitial pneumonia? Eur J Radiol. 2014;83(1):20–6.PubMedCrossRef
47.
Hatabu H, Hata A. Time to start describing fibrotic interstitial lung abnormalities in the chest CT report. Radiology. 2023;306(02):222274.
48.
Johkoh T, Muller NL, Colby TV, Ichikado K, Taniguchi H, Kondoh Y, et al. Nonspecific interstitial pneumonia: correlation between thin-section CT findings and pathologic subgroups in 55 patients. Radiology. 2002;225(1):199–204.PubMedCrossRef
49.
Silva CI, Muller NL, Hansell DM, Lee KS, Nicholson AG, Wells AU. Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology. 2008;247(1):251–9.PubMedCrossRef
50.
Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012;186(4):314–24.PubMedCrossRef
51.
Chung JH, Montner SM, Adegunsoye A, Oldham JM, Husain AN, Vij R, et al. CT findings associated with survival in chronic hypersensitivity pneumonitis. Eur Radiol. 2017;27(12):5127–35.PubMedCrossRef
52.
Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tuder R, Cool CD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med. 2013;107(8):1247–52.PubMedCrossRef
53.
Churg A, Sin DD, Everett D, Brown K, Cool C. Pathologic patterns and survival in chronic hypersensitivity pneumonitis. Am J Surg Pathol. 2009;33(12):1765–70.PubMedCrossRef
54.
Miller ER, Putman RK, Vivero M, Hung Y, Araki T, Nishino M, et al. Histopathology of interstitial lung abnormalities in the context of lung nodule resections. Am J Respir Crit Care Med. 2018;197(7):955–8.PubMedPubMedCentralCrossRef
55.
Hung YP, Hunninghake GM, Miller ER, Putman R, Nishino M, Araki T, et al. Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions. Hum Pathol. 2019;86:93–101.PubMedPubMedCentralCrossRef
56.
Chae KJ, Chung MJ, Jin GY, Song YJ, An AR, Choi H, et al. Radiologic-pathologic correlation of interstitial lung abnormalities and predictors for progression and survival. Eur Radiol. 2022;32(4):2713–23.PubMedCrossRef
57.
58.
Borie R, Kannengiesser C, Dupin C, Debray MP, Cazes A, Crestani B. Impact of genetic factors on fibrosing interstitial lung diseases. Incidence and clinical presentation in adults. Presse Med. 2020;49(2):104024.PubMedCrossRef
59.
Putman RK, Gudmundsson G, Araki T, Nishino M, Sigurdsson S, Gudmundsson EF, et al. The MUC5B promoter polymorphism is associated with specific interstitial lung abnormality subtypes. Eur Respir J. 2017;50(3):1700537.PubMedPubMedCentralCrossRef
60.
Hobbs BD, Putman RK, Araki T, Nishino M, Gudmundsson G, Gudnason V, et al. Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(11):1402–13.PubMedPubMedCentralCrossRef
61.
Moll M, Hobbs BD, Menon A, Ghosh AJ, Putman RK, Hino T, et al. Blood gene expression risk profiles and interstitial lung abnormalities: COPDGene and ECLIPSE cohort studies. Respir Res. 2022;23(1):157.PubMedPubMedCentralCrossRef
62.
Mathai SK, Newton CA, Schwartz DA, Garcia CK. Pulmonary fibrosis in the era of stratified medicine. Thorax. 2016;71(12):1154–60.PubMedCrossRef
63.
64.
Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–12.PubMedPubMedCentralCrossRef
65.
Evans CM, Fingerlin TE, Schwarz MI, Lynch D, Kurche J, Warg L, et al. Idiopathic pulmonary fibrosis: a genetic disease that involves mucociliary dysfunction of the peripheral airways. Physiol Rev. 2016;96(4):1567–91.PubMedPubMedCentralCrossRef
66.
Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309(21):2232–9.PubMedPubMedCentralCrossRef
67.
Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379(23):2209–19.PubMedPubMedCentralCrossRef
68.
Jonsson E, Ljung L, Norrman E, Freyhult E, Arlestig L, Dahlqvist J, et al. Pulmonary fibrosis in relation to genetic loci in an inception cohort of patients with early rheumatoid arthritis from northern Sweden. Rheumatology (Oxford). 2022;61(3):943–52.PubMedCrossRef
69.
Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5(8):639–47.PubMedPubMedCentralCrossRef
70.
Putman RK, Axelsson GT, Ash SY, Sanders JL, Menon AA, Araki T, et al. Interstitial lung abnormalities are associated with decreased mean telomere length. Eur Respir J. 2022;60(2):2101814.PubMedPubMedCentralCrossRef
71.
Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A. 2008;105(35):13051–6.PubMedPubMedCentralCrossRef
72.
Arish N, Petukhov D, Wallach-Dayan SB. The role of telomerase and telomeres in interstitial lung diseases: from molecules to clinical implications. Int J Mol Sci. 2019;20(12):2996.PubMedPubMedCentralCrossRef
73.
74.
Stuart BD, Choi J, Zaidi S, Xing C, Holohan B, Chen R, et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet. 2015;47(5):512–7.PubMedPubMedCentralCrossRef
75.
Snetselaar R, van Moorsel CHM, Kazemier KM, van der Vis JJ, Zanen P, van Oosterhout MFM, et al. Telomere length in interstitial lung diseases. Chest. 2015;148(4):1011–8.PubMedCrossRef
76.
77.
Ley B, Liu S, Elicker BM, Henry TS, Vittinghoff E, Golden JA, et al. Telomere length in patients with unclassifiable interstitial lung disease: a cohort study. Eur Respir J. 2020;56(2):2000268.PubMedCrossRef
78.
79.
80.
Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux ML, et al. Idiopathic pulmonary fibrosis: prospective, case-controlled study of natural history and circulating biomarkers. Chest. 2018;154(6):1359–70.PubMedCrossRef
81.
Bowman WS, Newton CA, Linderholm AL, Neely ML, Pugashetti JV, Kaul B, et al. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir Med. 2022;10(6):593–602.PubMedPubMedCentralCrossRef
82.
Axelsson GT, Gudmundsson G, Pratte KA, Aspelund T, Putman RK, Sanders JL, et al. The proteomic profile of interstitial lung abnormalities. Am J Respir Crit Care Med. 2022;206(3):337–46.PubMedPubMedCentralCrossRef
83.
Konigsberg IR, Borie R, Walts AD, Cardwell J, Rojas M, Metzger F, et al. Molecular signatures of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2021;65(4):430–41.PubMedPubMedCentralCrossRef
84.
Armstrong HF, Podolanczuk AJ, Barr RG, Oelsner EC, Kawut SM, Hoffman EA, et al. Serum matrix metalloproteinase-7, respiratory symptoms, and mortality in community-dwelling adults. MESA (Multi-Ethnic Study of Atherosclerosis). Am J Respir Crit Care Med. 2017;196(10):1311–7.PubMedPubMedCentralCrossRef
85.
Sanders JL, Putman RK, Dupuis J, Xu H, Murabito JM, Araki T, et al. The association of aging biomarkers, interstitial lung abnormalities, and mortality. Am J Respir Crit Care Med. 2021;203(9):1149–57.PubMedPubMedCentralCrossRef
86.
Ho JE, Gao W, Levy D, Santhanakrishnan R, Araki T, Rosas IO, et al. Galectin-3 is associated with restrictive lung disease and interstitial lung abnormalities. Am J Respir Crit Care Med. 2016;194(1):77–83.PubMedPubMedCentralCrossRef
87.
McGroder CF, Aaron CP, Bielinski SJ, Kawut SM, Tracy RP, Raghu G, et al. Circulating adhesion molecules and subclinical interstitial lung disease: the multi-ethnic study of atherosclerosis. Eur Respir J. 2019;54(3):1900295.PubMedPubMedCentralCrossRef
88.
Kim JS, Axelsson GT, Moll M, Anderson MR, Bernstein EJ, Putman RK, et al. Associations of monocyte count and other immune cell types with interstitial lung abnormalities. Am J Respir Crit Care Med. 2022;205(7):795–805.PubMedCrossRef
89.
Machahua C, Buendia-Roldan I, Ocana-Guzman R, Molina-Molina M, Pardo A, Chavez-Galan L, et al. CD4+T cells in ageing-associated interstitial lung abnormalities show evidence of pro-inflammatory phenotypic and functional profile. Thorax. 2021;76(2):152–60.PubMedCrossRef
90.
Ortiz-Quintero B, Buendia-Roldan I, Ramirez-Salazar EG, Balderas-Martinez YI, Ramirez-Rodriguez SL, Martinez-Espinosa K, et al. Circulating microRNA signature associated to interstitial lung abnormalities in respiratory asymptomatic subjects. Cells. 2020;9(6):1556.PubMedPubMedCentralCrossRef
91.
d’Alessandro M, Bergantini L, Cameli P, Vietri L, Lanzarone N, Alonzi V, et al. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. Biomark Med. 2020;14(8):665–74.PubMedCrossRef
92.
Kinoshita F, Hamano H, Harada H, Kinoshita T, Igishi T, Hagino H, et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med. 2004;98(11):1131–7.PubMedCrossRef
93.
Ichiyasu H, Ichikado K, Yamashita A, Iyonaga K, Sakamoto O, Suga M, et al. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia. Respiration. 2012;83(3):190–7.PubMedCrossRef
94.
Bergantini L, Bianchi F, Cameli P, Mazzei MA, Fui A, Sestini P, et al. Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6. Dis Markers. 2019;2019:8565423.PubMedPubMedCentralCrossRef
95.
Khan FA, Stewart I, Saini G, Robinson KA, Jenkins RG. A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis. Eur Respir J. 2022;59(4):2101612.PubMedPubMedCentralCrossRef
96.
Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015;67(1):28–38.PubMedPubMedCentralCrossRef
97.
Morais A, Beltrao M, Sokhatska O, Costa D, Melo N, Mota P, et al. Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir Med. 2015;109(8):1063–8.PubMedCrossRef
98.
•• Hunninghake GM, Goldin JG, Kadoch MA, Kropski JA, Rosas IO, Wells AU, et al. Detection and early referral of patients with interstitial lung abnormalities: an expert survey initiative. Chest. 2022;161(2):470–82. This paper provided practical guidance based ILD expert consensus regarding the identification of clinically relevant ILA, subsequent referral, and follow-up.PubMedCrossRef
99.
Patel AS, Miller E, Regis SM, Hunninghake GM, Price LL, Gawlik M, et al. Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis. Respir Res. 2023;24(1):49.PubMedPubMedCentralCrossRef
100.
101.
Barnes H, Humphries SM, George PM, Assayag D, Glaspole I, Mackintosh JA, et al. Machine learning in radiology: the new frontier in interstitial lung diseases. Lancet Digit Health. 2022;5(1):e41–50.PubMedCrossRef
102.
Walsh SL, Calandriello L, Sverzellati N, Wells AU, Hansell DM, Consort UIPO. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax. 2016;71(1):45–51.PubMedCrossRef
103.
Walsh SLF, Humphries SM, Wells AU, Brown KK. Imaging research in fibrotic lung disease; applying deep learning to unsolved problems. Lancet Respir Med. 2020;8(11):1144–53.PubMedCrossRef
104.
Shaish H, Ahmed FS, Lederer D, D’Souza B, Armenta P, Salvatore M, et al. Deep learning of computed tomography virtual wedge resection for prediction of histologic usual interstitial pneumonitis. Ann Am Thorac Soc. 2021;18(1):51–9.PubMedPubMedCentralCrossRef
105.
Humphries SM, Mackintosh JA, Jo HE, Walsh SLF, Silva M, Calandriello L, et al. Quantitative computed tomography predicts outcomes in idiopathic pulmonary fibrosis. Respirology. 2022;27(12):1045–53.PubMedPubMedCentralCrossRef
106.
Handa T, Tanizawa K, Oguma T, Uozumi R, Watanabe K, Tanabe N, et al. Novel artificial intelligence-based technology for chest computed tomography analysis of idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2022;19(3):399–406.PubMedCrossRef
107.
Furukawa T, Oyama S, Yokota H, Kondoh Y, Kataoka K, Johkoh T, et al. A comprehensible machine learning tool to differentially diagnose idiopathic pulmonary fibrosis from other chronic interstitial lung diseases. Respirology. 2022;27(9):739–46.PubMedCrossRef
108.
Walsh SLF, Mackintosh JA, Calandriello L, Silva M, Sverzellati N, Larici AR, et al. Deep learning-based outcome prediction in progressive fibrotic lung disease using high-resolution computed tomography. Am J Respir Crit Care Med. 2022;206(7):883–91.PubMedCrossRef
109.
Kim MS, Choe J, Hwang HJ, Lee SM, Yun J, Kim N, et al. Interstitial lung abnormalities (ILA) on routine chest CT: Comparison of radiologists’ visual evaluation and automated quantification. Eur J Radiol. 2022;157: 110564.PubMedCrossRef
110.
Ash SY, Harmouche R, Ross JC, Diaz AA, Hunninghake GM, Putman RK, et al. The objective identification and quantification of interstitial lung abnormalities in smokers. Acad Radiol. 2017;24(8):941–6.PubMedCrossRef
111.
Bermejo-Pelaez D, Ash SY, Washko GR, San Jose Estepar R, Ledesma-Carbayo MJ. Classification of interstitial lung abnormality patterns with an ensemble of deep convolutional neural networks. Sci Rep. 2020;10(1):338.PubMedPubMedCentralCrossRef
Metadata
Title
Interstitial Lung Abnormalities (ILA) and Pulmonary Fibrosis
Authors
Noriaki Wada
Kyung Soo Lee
Hiroto Hatabu
Publication date
02-04-2024
Publisher
Springer US
Published in
Current Pulmonology Reports
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-024-00350-3
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits